The timing could hardly have been better. Just three days after the US department of energy designated helium a critical material, Nasdaq- and JSE-listed company ASP Isotopes announced that its South African subsidiary, Renergen, had achieved stable liquid helium production at its Virginia Gas Project in the Free State.
With Middle Eastern supply disruptions worsening global helium shortages, the world desperately needs alternative sources. Yet investors were hardly celebrating. At about $2.13, ASP’s shares have lost nearly 86% of their value since peaking at $14.49 in October 2025, and now trade at about half their $4 Nasdaq listing price in November 2022.
For former Renergen shareholders, the losses have been particularly painful. When ASP acquired the company in January they received 0.09196 ASP shares for every Renergen share. At the prevailing ASP price and exchange rate, that values their former shares at just 326c apiece — barely above Renergen’s March 2025 low of 300c and about 65% below its final JSE closing price of 920c.
Has the market become excessively pessimistic, or is it finally losing patience with a business that has consistently promised more than it has delivered?
Founded in 2021 by CEO Paul Mann and COO Robert Ainscow, ASP Isotopes has assembled an unusually diverse collection of businesses.
At its core is isotope enrichment — separating different versions of the same chemical element that have the identical numbers of protons but different numbers of neutrons. Certain isotopes have properties that make them particularly valuable in medicine, semiconductors and other hi-tech industries. ASP uses two technologies to separate the isotopes: an aerodynamic process that separates them in gases, and a laser-based system capable of separating isotopes of metals.
ASP’s South African plants are developing the isotope silicon-28 for advanced semiconductors, carbon-14 for pharmaceutical research and ytterbium-176, which can be used to produce radioactive material, for cancer treatment.
ASP Isotopes subsidiary Quantum Leap Energy has the even grander ambition of producing specialised uranium fuel for next-generation nuclear reactors. It recently reached an agreement with the South African Nuclear Energy Corporation to establish a uranium enrichment venture at Pelindaba, though commercial viability remains unproven.
ASP also operates radiopharmacies through PET Labs in South Africa and acquired businesses in the US. These facilities produce radioactive medicines used primarily in medical imaging, particularly for detecting cancer. Unlike ASP’s enrichment operations, these companies already generate meaningful revenue. Another subsidiary, Alpa Theranostics, is developing experimental cancer treatments using antibodies derived from alpacas.
It is an ambitious portfolio for a company valued at just $327m.
There has been encouraging technical progress. But turning scientific breakthroughs into profitable commercial operations has proved considerably harder. Mann concedes as much: “Scaling these up to commercial processes has proved a lot more challenging than we expected.”
Meaningful revenues from the enrichment plants remain elusive, despite initial expectations that commercial deliveries would begin in 2025.
Anchor Capital analyst Steph Erasmus, whose firm holds the JSE-listed shares in its Anchor FR SA Equity Fund, sees both sides of the investment case. “ASP has real assets and real potential, but it has also missed deadlines, and the outcome depends on delivery,” he says. “I think the potential reward justifies a responsibly sized position.”
ASP’s acquisition of Renergen brought with it an asset of enormous potential and an equally impressive record of disappointment.
Renergen’s Virginia Gas Project contains natural gas with exceptionally high helium concentrations, far above those typically found in conventional helium-producing gas fields.
Helium’s unique cooling properties make it indispensable for MRI scanners, semiconductor manufacturing and scientific instruments, with growing applications in quantum computing and aerospace.
But favourable market conditions count for little if Renergen cannot deliver the product.
The company has a long history of missed production deadlines stretching back to 2018. In December 2024, it announced that helium production had stabilised. This was followed in March 2025 by its first commercial delivery — a relatively small dewar rather than the large ISO containers intended for exports.
The breakthrough proved short-lived. Just 52.6kg of helium was produced in the six months to August 2025; operations were suspended because insufficient gas feed made continued production uneconomic.
Now ASP has again announced stable helium production, but without revealing the quantity. The omission prompted long-time Renergen critic and activist investor Albie Cilliers to question the announcement on X.
At an investor presentation on October 28, Mann was asked directly about the current helium production rate. Instead of disclosing output, he cited the plant’s design capacity of 70,000 cubic feet a day and said it should take approximately two weeks to fill a large ISO container at full production.
ASP did not respond to the FM’s questions, submitted before publication, about actual helium output, gas-feed volumes and progress towards full production capacity.
Erasmus is cautious. “I’ve visited the Virginia site several times and seen the plant and infrastructure being built. But that’s different from proving the wells can deliver gas at the flow rates the plant needs, which is what Renergen still has to show.” His yardstick is straightforward: “I’ll call it commercial only once helium deliveries, revenue and profit show up in the reported results.”
The company now expects its first full ISO-container shipment in December, with another in January.
The Virginia project already produces liquefied natural gas for industrial customers, providing an established revenue stream alongside the operation’s helium ambitions. This could become increasingly valuable, as South Africa faces an industrial gas shortage caused by declining supplies from Sasol’s Mozambican operations. Though Phase 1 is far too small to bridge the gap, a substantial expansion could make a meaningful contribution.
That makes Renergen’s Phase 2 development particularly important. Originally envisaged at about 13 times the size of Phase 1 and costing more than $1bn, it was expected to begin construction before year-end and take approximately 44 months to complete. However, an October US regulatory filing revealed that ASP was reconsidering the project’s design, scale and development sequence, potentially delaying construction and production.
Funding remains another obstacle. More than three years after Renergen announced proposed debt financing from the US International Development Finance Corp and Standard Bank, neither lender has made a binding Phase 2 commitment. Substantial equity funding and additional customer contracts are also needed.
Reverse merger
A proposed separate Nasdaq listing of Renergen through a reverse merger with Endra Life Sciences could help raise capital. The transaction envisages approximately $30m in external investment, with ASP contributing a further $20m and retaining control of the new company, to be called 4K Resources. Completion remains subject to several conditions.
Erasmus believes Phase 2 is the larger opportunity, but not an imminent one. “I imagine proof of concept from Phase 1 is key to funding a Phase 2, so it’s probably a story for the next few years,” he says.
The gap between ambition and delivery is particularly striking when measured against executive remuneration. ASP’s three top executives received combined compensation valued at more than $28m in 2025, mostly in share-based awards, some of which depend on a future listing of subsidiary Quantum Leap Energy.
By comparison, ASP’s continuing operations generated just $5.67m in revenue that year, alongside substantial losses.
Shareholders have also faced substantial dilution, with ASP’s share count more than quadrupling since its 2022 Nasdaq listing.
Mann has an impressive financial résumé, if less experience running industrial plants. A Cambridge-trained chemical engineer, he worked at Deutsche Bank, Morgan Stanley, Soros Fund Management and Highbridge Capital before serving as CFO of biotechnology business PolarityTE from 2018 to 2020. PolarityTE filed for bankruptcy in 2023, well after his departure.
Erasmus draws a distinction between financial execution and operations. “I think management has a strong record of raising capital and completing deals,” he says. “[But it] has repeatedly missed operational deadlines, creating uncertainty.”
In his view, the share price collapse cannot be attributed to one factor, but missed deadlines have done little to inspire confidence.
Mann is still targeting more than $300m in annual ebitda by 2031, much of it dependent on developing Renergen’s Phase 2 and commercialising businesses that have yet to prove themselves.
ASP ended June with approximately $255m in cash and short-term investments, but operating cash outflow reached $41.1m during the first half.
Erasmus is reluctant to assign a valuation to the collection of businesses until delivery improves. His watchlist includes profitable helium sales from Virginia, Renergen’s own Nasdaq listing, the first profitable isotope sales and an eventual listing of Quantum Leap Energy. Risks include further delays, inadequate gas flows and the need to raise more money.
There may well be substantial value in ASP’s technology and helium resources. But after years of ambitious forecasts and missed deadlines, shareholders are entitled to demand more than promises. For now, a container filled with helium and delivered to a paying customer would speak louder than another investor presentation.
